Sunil Lalla, MD
Pulmonary Disease · Fort Myers, FLNPI 1407841760
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,017 of the $8,334 with a category attached, or 72.2%. Intuitive Surgical accounts for 83.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $4,016 and has fallen 92.3% since, to $308 in 2025.
Across 53 payments — averaging $157.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Johnson & Johnson$322
- Pulmonx Corporation$186
- AstraZeneca$154
- Sanofi$132
- Covidien LP$116
- plus $429 from 13 others
What the payments were for
- Travel & lodging$92811%
- Food & beverage$1,36816%
- Education$6,01772%
- Gifts$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $6,996 |
| Johnson & Johnson(2 entities) | 4 | $322 |
| Pulmonx Corporation | 3 | $186 |
| AstraZeneca | 9 | $154 |
| Sanofi | 4 | $132 |
| Covidien LP | 1 | $116 |
| Merck | 3 | $92 |
| GSK | 3 | $56 |
| Amgen | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Baxter Healthcare | 1 | $31 |
| Bayer | 1 | $23 |
| Insmed, Inc. | 1 | $21 |
| Circassia Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| United Therapeutics Corporation | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,334 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 12 | $154,085 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $65,871 |
| EliquisApixaban | 27 | $34,442 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $29,422 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $27,802 |
| OzempicSemaglutide | 15 | $27,066 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $25,297 |
| JanuviaSitagliptin Phosphate | 13 | $13,092 |
| MounjaroTirzepatide | 11 | $11,545 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $11,189 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $10,749 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $5,511 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,309 |
| Ventolin HfaAlbuterol Sulfate | 37 | $2,034 |
| Ranolazine ErRanolazine | 14 | $1,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $49 | $154,08512 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $56 | $118,970107 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $154 | $40,61149 claims |
| MerckJanuvia | $92 | $13,09213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Fort Myers
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.